Catalog No.
DHC12503
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
AICD-57, A4, Beta-CTF, Protease nexin-II, Gamma-CTF(50), ABPP, S-APP-beta, APP, Abeta40, Abeta42, AID(59), Amyloid intracellular domain 59, AID(57), S-APP-alpha, Gamma-CTF(59), Beta-secretase C-terminal fragment, Amyloid-beta precursor protein, Amyloid precursor protein, Beta-APP42, PreA4, Alzheimer disease amyloid protein, APPI, PN-II, AICD-59, Alpha-secretase C-terminal fragment, Amyloid-beta A4 protein, Amyloid intracellular domain 57, CVAP, Amyloid intracellular domain 50, Beta-APP40, AD1, Cerebral vascular amyloid peptide, AID(50), Alpha-CTF, Gamma-CTF(57), AICD-50
Concentration
1.79 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P05067
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
R1450, CAS: 1043556-46-2
Clone ID
Gantenerumab
Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval, PMID: 32787971
A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease, PMID: 29221491
Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis, PMID: 31831056
Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β, PMID: 21955818
Gantenerumab for the treatment of Alzheimer's disease, PMID: 22583155
Profile of gantenerumab and its potential in the treatment of Alzheimer's disease, PMID: 24255592
Drug candidates in clinical trials for Alzheimer's disease, PMID: 28720101
Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease, PMID: 25081412
Computational Investigation of Gantenerumab and Crenezumab Recognition of Aβ Fibrils in Alzheimer's Disease Brain Tissue, PMID: 32991803
Anti-amyloid-β protein agents for the treatment of Alzheimer's disease: an update on emerging drugs, PMID: 32772738
Kinetic fingerprints differentiate the mechanisms of action of anti-Aβ antibodies, PMID: 32989305
Passive antiamyloid immunotherapy for Alzheimer's disease, PMID: 32040044
The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset, PMID: 29037101
Lessons Learnt from the Second Generation of Anti-Amyloid Monoclonal Antibodies Clinical Trials, PMID: 33321511
Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β, PMID: 29686315
A Phase I Study to Assess the Effect of Speed of Injection on Pain, Tolerability, and Pharmacokinetics After High-volume Subcutaneous Administration of Gantenerumab in Healthy Volunteers, PMID: 31883703
Reproductive and developmental toxicology studies with gantenerumab in PS2APP transgenic mice, PMID: 28754630
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab, PMID: 21987394
Thirty-Six-Month Amyloid Positron Emission Tomography Results Show Continued Reduction in Amyloid Burden with Subcutaneous Gantenerumab, PMID: 33336218
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease, PMID: 34155411
Correction to: A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease, PMID: 30261916
Combined treatment with a BACE inhibitor and anti-Aβ antibody gantenerumab enhances amyloid reduction in APPLondon mice, PMID: 25164658
Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward, PMID: 24490853
Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies, PMID: 28066098
Alzheimer disease immunotherapeutics: then and now, PMID: 25483498
Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?, PMID: 24445401
Therapeutic strategies for Alzheimer's disease in clinical trials, PMID: 26721364
Structural aspects of Alzheimer's disease immunotherapy targeted against amyloid-beta peptide, PMID: 29663816
Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?, PMID: 24981190
Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer's disease patients, PMID: 27678025
Can Anti-β-amyloid Monoclonal Antibodies Work in Autosomal Dominant Alzheimer Disease?, PMID: 33575481
Current and Emerging Pharmacological Targets for the Treatment of Alzheimer's Disease, PMID: 31594236
Which are the antibodies to watch in 2013?, PMID: 23254906
Antibodies to watch in 2018, PMID: 29300693
The Alzheimer disease market, PMID: 26388231
Developing Disease-Modifying Treatments in Alzheimer's Disease - A Perspective from Roche and Genentech, PMID: 29181492
[Antibody therapy for Alzheimer's disease], PMID: 22277519
Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: end of beginning or beginning of end?, PMID: 24053611
Critical Appraisal of Amyloid Lowering Agents in AD, PMID: 34110536
Treatments for Alzheimer's disease emerge, PMID: 34353940
Significance of Oligomeric and Fibrillar Species in Amyloidosis: Insights into Pathophysiology and Treatment, PMID: 34443678
Passive immunotherapy for Alzheimer's disease: what have we learned, and where are we headed?, PMID: 23299379
Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease, PMID: 33831607
Antibody drugs for Alzheimer's show glimmers of promise, PMID: 26223602
Comparing the efficacy and neuroinflammatory potential of three anti-abeta antibodies, PMID: 26433971
SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA), PMID: 30486882
Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer's Disease: Need for Prognostic Biomarkers?, PMID: 27031492
Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer's Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression, PMID: 34198582
Aducanumab produced a clinically meaningful benefit in association with amyloid lowering, PMID: 33971962
For research use only. Not for human or drug use.
